Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
Integrin alpha-5 (ITGA5) |
Target Info
|
Antagonist |
[2], [3], [4] |
| Integrin beta-1 (ITGB1) |
Target Info
|
Antagonist |
[2], [3], [4] |
| References |
Top |
| REF 1 |
ClinicalTrials.gov (NCT00536016) A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD. U.S. National Institutes of Health.
|
| REF 2 |
An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85.
|
| REF 3 |
Modulation of hypoxia-induced neovascularization by JSM6427, an integrin alpha5beta1 inhibiting molecule. Curr Eye Res. 2007 Sep;32(9):801-12.
|
| REF 4 |
Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol. 2006 Jun;69(6):1820-8.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
